Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

AAIPharma Expands Capacity of Parenteral Manufacturing Facility

Published: Friday, December 28, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Addition of on-site formulation development capabilities and enhanced analytical instrumentation.

AAIPharma Services Corp. has announced that it is expanding the capacity and capabilities of its parenteral manufacturing facility in Charleston, S.C.

Facility expansions currently underway at AAIPharma’s Charleston location include the installation of compounding and aseptic processing suites to contain a newly acquired Monoblock vial filling machine, expansion of the microbiology laboratory and addition of on-site formulation development capabilities and enhanced analytical instrumentation.

“One of AAIPharma’s key offerings is the ability to provide our clients with low line loss techniques,” said Rob Goshert, vice president of sales and client services.

Goshert continued, “We are often challenged by our clients to minimize consumption of their expensive active ingredients, and one way AAIPharma has answered this challenge is through the use of specialized filling processes designed to minimize product loss.”

AAIPharma’s FDA- and EU-approved facility utilizes disposable product contact components and maintains redundant critical capabilities to minimize potential downtime.

The fill and finish capabilities support vial sizes from 2 mL to 50 mL and can include 100% weight check.

Manufactured products include solutions, lyophilized products, emulsions and suspensions with batch sizes ranging from a few hundred vials to twenty-thousand, or more.

“In addition to the new fill line, integration of our formulation development and technical services capabilities through the build-out of a new pilot suite allows us to seamlessly support the manufacturing process from development through scale-up, further enhancing our compound to clinic™ strategy” said Paul Maffuid, Ph.D., vice president of pharmaceutical operations.

Maffuid continued, “Expansion of the existing laboratories with a new clean room for on-site sterility testing using isolator technology continues our primary objective of providing a world-class parenteral manufacturing facility with all supporting infrastructure under one roof.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AAIPharma and CML Announce the Appointments of Vice Presidents
Appointment of Ted Dolan as Vice President, API Operations and Syed T. Husain as Vice President, API Business Unit.
Friday, October 10, 2014
AAIPharma and CML Appoints CEO
Appointment of Stephan Kutzer as Chief Executive Officer, effective August 1, 2014.
Thursday, July 10, 2014
AAIPharma and CML Announce Patrick Walsh’s Resignation as CEO
Both Companies announces the appointment of interim CEO, Susan Nestegard.
Saturday, April 12, 2014
Cambridge Major Laboratories and AAIPharma Services Announce Merger
Merger is expected to close by the end of October 2013.
Thursday, October 03, 2013
AAIPharma Services Acquires Celsis Analytical Services
Combined company creates one of the leading material testing businesses offering a comprehensive range of testing services to numerous industries.
Monday, February 13, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos